Upregulation of circulating microRNA-134 in adult-onset Still’s disease and its use as potential biomarker

Tsai-Ling Liao¹,², Yi-Ming Chen¹,²,³,⁴, Chia-Wei Hsieh²,⁴, Hsin-Hua Chen⁴,¹,²,³,⁴, Hsiu-Chin Lee¹,⁵, Wei-Ting Hung³,⁶, Kuo-Tung Tang²,⁴ & Der-Yuan Chen²,³,⁴,⁶

Adult-onset Still’s disease (AOSD) is a multi-systemic inflammatory disorder of unknown etiology. To date, no single diagnostic test is available for AOSD. Herein, we investigated the pathogenic role of microRNAs in AOSD. MicroRNA profiles in plasma from AOSD patients and healthy controls were analyzed by microarray analysis, followed by quantitative reverse transcription PCR validation. The biological functions of microRNAs were evaluated using in vitro cell-based assay. Among the differentially expressed microRNAs, microRNA-134 (miR-134) expression was positively correlated with AOSD activity scores and significantly decreased after effective treatment. An increased miR-134 level is significantly associated with the activation of Toll-like receptor 3 (TLR3). The reporter assay identified IL-18 binding protein (IL-18BP) as the target of miR-134. A negative correlation between miR-134 expression and IL-18BP mRNA levels were detected in peripheral blood cells following TLR3 ligand treatment. Lower plasma IL-18BP levels and higher IL-18 levels were also observed in active AOSD patients who had higher miR-134 expression than inactive patients. Upregulation of circulating miR-134 was associated with elevated IL-18 levels by targeting IL-18BP in AOSD patients and was positively correlated with disease activity, suggesting its involvement in AOSD pathogenesis. MiR-134 may be a novel activity indicator or potential prognostic biomarker in AOSD.

MicroRNAs (MiRNAs) are short non-coding RNAs composed of approximately 20 to 24 nucleotides that mediate messenger (m)RNA cleavage, translational repression, or mRNA destabilization¹–³, and currently more than 2,000 human miRNAs are registered (miRBase Release 20.0)⁴. MiRNAs have recently been identified as immune regulators that post-transcriptionally repress target mRNAs expression⁵, and they have diverse functions in immune cell development, particularly the development of Th17 cells²–³. The deregulated expression of miRNAs has been observed in different pathological conditions, including rheumatic and inflammatory diseases⁵–⁸. Recent studies have revealed that miRNAs are present in a remarkably stable form in plasma and are thought to have potential as clinical biomarkers or therapeutic targets⁹–¹¹.

Adult-onset Still’s disease (AOSD) is a rare inflammatory disease of unknown etiology that usually affects young adults, which is characterized by fever, rash, arthritis, variable multisystemic involvement, and an increase of acute phase reactants¹²,¹³. To date, determining predictive factors of outcome and to drawing guidelines for patient management remains difficult¹⁴,¹⁵. Previous studies, including ours, have demonstrated elevated levels of proinflammatory cytokines including interleukin (IL)-1β, IL-6, IL-18, tumor necrosis factor (TNF)-α, and type 1 T helper (Th1)- or Th17-derived cytokines in AOSD patients¹⁶–²¹. Moreover, an increase of spontaneous and IL-18-induced apoptosis plays an important role in AOSD pathogenesis²². Curtale et al. also demonstrated that...
miR-146a was involved in T-cell activation and could modulate activation-induced apoptosis. These observations led us to hypothesize that miRNAs may play an important role in AOSD pathogenesis. No data are available, however, concerning the expression of circulating miRNAs in AOSD patients.

In the present study, we investigated differential miRNA expression in plasma from AOSD patients compared with healthy controls using microarray profiling followed by quantitative reverse transcription PCR (QRT-PCR) validation. The associations of candidate miRNAs expression with clinical activity scores or disease outcome were examined in AOSD patients. We used a bioinformatics tool to search for potential targets of candidate miRNAs and subsequently used 3′ untranslated region (UTR) reporter assay for validation. Additionally, we explored the biologic roles of candidate miRNAs in AOSD pathogenesis using an in vitro cell-based functional assay.

Results
Clinical characteristics of AOSD patients. Among the 12 active untreated AOSD patients in the microarray analysis, common manifestations included spiking fever (9, 75.0%), evanescent rash (8, 66.7%), sore throat (7, 58.3%) and arthritis (5, 41.7%). Lymphadenopathy and hepatosplenomegaly were noted in 4 (33.3%) and 3 (25.0%) patients respectively. There were no significant differences in the age at entry (mean age ± SD, 34.6 ± 12.7 versus 34.7 ± 13.3 years) or in the proportion of females (both were 66.7%) between the AOSD patients and healthy controls (HC).

After initial investigation for miRNAs, all AOSD patients received corticosteroids with/without non-steroidal anti-inflammatory drugs (NSAIDs). The conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) used were methotrexate (10 patients), hydroxychloroquine (8 patients), and sulfasalazine (5 patients). During the 2-year follow-up period, 3 patients received therapy with IL-6 receptor inhibitor (tocilizumab).

Differentially expressed miRNAs using microarray analysis and QRT-PCR. The results of gel electrophoresis confirmed the good quality of RNA isolation in each group as shown in Supplementary Fig. S1. After normalization of the raw data, we observed 28 miRNAs distinctively expressed in plasma from AOSD patients, 12 miRNAs were up-regulated and 16 miRNAs were down-regulated in AOSD patients compared with the HC group (Table 1 and Fig. 1a). Two differentially expressed miRNAs (miR-134 and miR-149) showed consistent results in both QRT-PCR and microarray analysis (Fig. 1b).

| Up-regulated miRNAs | Fold change (median value) | Down-regulated miRNAs | Fold change (median value) |
|---------------------|---------------------------|------------------------|---------------------------|
| hsa-miR-575         | 18.099                    | hsa-miR-940            | 0.169                     |
| hsa-miR-4299        | 14.766                    | hsa-miR-4313           | 0.177                     |
| hsa-miR-15b         | 11.140                    | hsa-miR-1280           | 0.189                     |
| hsa-miR-223         | 10.089                    | hsa-miR-1281           | 0.206                     |
| hsa-miR-142-3p      | 5.860                     | hsa-miR-486-5p         | 0.220                     |
| hsa-miR-451         | 5.501                     | Has-let-7i-1           | 0.228                     |
| hsa-miR-134         | 4.660                     | hsa-miR-191            | 0.232                     |
| hsa-miR-187         | 4.323                     | hsa-miR-1234           | 0.243                     |
| hsa-miR-19a         | 3.509                     | hsa-miR-1825           | 0.267                     |
| hsa-miR-30b         | 3.507                     | hsa-miR-129-3p         | 0.269                     |
| hsa-miR-3196        | 3.491                     | hsa-miR-1238           | 0.276                     |
| hsa-miR-425         | 3.322                     | hsa-miR-1539           | 0.281                     |
| hsa-miR-149         | 3.287                     | hsa-miR-149            | 0.287                     |
| hsa-miR-425         | 2.945                     | hsa-miR-1225-3p        | 0.295                     |
| hsa-miR-21          | 3.132                     | hsa-miR-21             | 0.313                     |

Table 1. Differentially expressed miRNAs in plasma from AOSD patients compared with healthy controls, identified by miRNA microarray analysis. AOSD: adult-onset Still's disease; miRNA: microRNA. §Fold change: if the number >3.00 or <0.330, the difference is considered significant.

miR-146a was involved in T-cell activation and could modulate activation-induced apoptosis. These observations led us to hypothesize that miRNAs may play an important role in AOSD pathogenesis. No data are available, however, concerning the expression of circulating miRNAs in AOSD patients.

In the present study, we investigated differential miRNA expression in plasma from AOSD patients compared with healthy controls using microarray profiling followed by quantitative reverse transcription PCR (QRT-PCR) validation. The associations of candidate miRNAs expression with clinical activity scores or disease outcome were examined in AOSD patients. We used a bioinformatics tool to search for potential targets of candidate miRNAs and subsequently used 3′ untranslated region (UTR) reporter assay for validation. Additionally, we explored the biologic roles of candidate miRNAs in AOSD pathogenesis using an in vitro cell-based functional assay.

Correlation between miR-134 expression and activity scores in AOSD patients. Among the 12 differentially expressed miRNAs, the miR-134 expression determined by QRT-PCR assay was positively correlated with the clinical activity scores of AOSD patients (Fig. 1c). However, there were no significant associations of miR-134 expression with clinical manifestations in AOSD patients. Significant decreases in miR-134 expression (mean ± SEM, 5.30 ± 2.19 vs. 0.84 ± 0.56, P < 0.05) that paralleled the clinical remission (activity score 5.7 ± 0.5 vs. 2.0 ± 0.4, P < 0.05) were observed in AOSD patients after 6-month therapy (Fig. 1d). Although the other differentially expressed miRNA in AOSD patients, miR-149, may be an immune modulator for the TLR/MyD88 signaling pathway in murine macrophages, we did not further investigate its pathogenic role due to the lack of a significant association with AOSD disease activity.

Correlation between miR-134 expression and activity scores in AOSD patients.

Correlation between miR-134 expression and activity scores in AOSD patients. Among the 12 differentially expressed miRNAs, the miR-134 expression determined by QRT-PCR assay was positively correlated with the clinical activity scores of AOSD patients (Fig. 1c). However, there were no significant associations of miR-134 expression with clinical manifestations in AOSD patients. Significant decreases in miR-134 expression (mean ± SEM, 5.30 ± 2.19 vs. 0.84 ± 0.56, P < 0.05) that paralleled the clinical remission (activity score 5.7 ± 0.5 vs. 2.0 ± 0.4, P < 0.05) were observed in AOSD patients after 6-month therapy (Fig. 1d). Although the other differentially expressed miRNA in AOSD patients, miR-149, may be an immune modulator for the TLR/MyD88 signaling pathway in murine macrophages, we did not further investigate its pathogenic role due to the lack of a significant association with AOSD disease activity.
Figure 1. Increased microRNA-134 (miR-134) levels in patients with active adult-onset Still’s disease (AOSD) is associated with disease activity and induced by Toll-like receptor 3 (TLR3) ligand stimulation. (a) The differentially expressed microRNAs (miRNAs) in plasma from patients with AOSD and healthy controls (HC) identified using microarray analysis. Hierarchical clustering of miRNA profiles in AOSD patients group and HC group. Relative expression levels of miRNAs are depicted according to a color scale (red represents relative expression greater than the median expression level across all samples and green represents an expression level lower than the median). (b) Validation of miRNA microarray with quantitative reverse transcription PCR (QRT-PCR) for the two randomly selected differentially expressed miRNAs in AOSD patients. (c) A significant correlation between disease activity and miR-134 expression determined by QRT-PCR assay in AOSD patients. (d) Significant decreases in miR-134 expression levels paralleled the clinical remission in AOSD patients after 6 months of therapy. (e) Analysis of miR-134 expression in response to a panel of innate immunity Toll-like receptors (TLRs) ligands stimulation. The peripheral blood mononuclear cells (PBMCs) from patients with AOSD were treated with the indicated stimuli for 24 h. MiR-134 expression was analyzed by QRT-PCR and normalized using Rnu6 levels. (f) Kinetics of TLR3 ligand induction of miR-134.
Association of miR-134 expression and disease outcome in AOSD patients. Defined as described in previous studies, disease outcome including systemic inflammatory pattern and chronic articular pattern was determined for each AOSD patient. Among 23 AOSD patients, 17 (73.9%) had a systemic inflammatory pattern and 6 (26.1%) had chronic articular pattern. As illustrated in Supplementary Fig. S2a, a higher miR-134 expression was observed in AOSD patients with the systemic inflammatory pattern than in those with chronic articular pattern (96.04 ± 35.74 fold vs. 3.04 ± 0.36 fold, P = 0.143).

To verify that miR-134 was a potential biomarker for AOSD, we screened circulating miR-134 levels in plasma from patients with AOSD or systemic lupus erythematosus (SLE), which partially shared clinical manifestations with AOSD, as the disease control. The QRT-PCR results (Supplementary Fig. S2b) showed significantly higher miR-134 levels in AOSD patients (n = 30) [active AOSD (n = 12, 128.60 ± 47.72 fold); inactive AOSD (n = 18, 10.00 ± 4.55 fold)] than in SLE patients (n = 22, 2.86 ± 0.53 fold) and healthy controls (n = 22, 5.25 ± 2.26 fold) (both P < 0.01). The upregulation of miR-134 was also detected in PBMCs from AOSD patients [active AOSD (n = 6, 147.70 ± 28.25 fold); inactive AOSD (n = 8, 1.91 ± 0.44 fold), but not in SLE patients (n = 14, 0.16 ± 0.04 fold) or healthy controls (n = 7, 0.53 ± 0.13 fold) (both P < 0.0001). (Supplementary Fig. S2c). The upregulation of miR-134 was positively correlated with disease activity (active AOSD vs. inactive AOSD: 147.70 ± 28.25 fold vs. 1.91 ± 0.44 fold, P < 0.0001).

Increased miR-134 levels in PBMCs following TLR3 ligand stimulation. To explore the mechanism related to the upregulation of miR-134 in active AOSD, we further investigated whether innate immunity-associated Toll-like receptors (TLRs) might regulate miR-134 expression. Significantly increased miR-134 levels (3.81 ± 0.09 fold, P < 0.01) in PBMCs from AOSD patients after TLR3 ligand polyriboinosinic: polyribocytidylic acid [poly (I:C)] treatment suggest that double stranded RNA (dsRNA) might contribute to miR-134 up-regulation (Fig. 1e). This dynamic result showed that the expression of miR-134 reached a plateau at 24 h after poly (I:C) stimulation (Fig. 1f).

To support the findings in AOSD patients, we also examined the miR-134 expression levels in THP-1 cells treated with the different Toll-like receptor agonists including TLR3 ligand, poly (I:C). In the THP-1 cells, significantly increased miR-134 levels were also apparent in cells with the mutant at the pupative binding site was used as a control. Our results showed that miR-134 cloning the predicted seed sequence in the human IL-18BP 3'UTR construct or pMIR-REPORT plasmid (Fig. 3b), indicating that IL-18BP is the target of miR-134 and could mimic significantly decreased (P < 0.01) while miR-134 inhibitors significantly enhanced the luciferase activity in cells transfected with the IL-18BP 3'UTR plasmid compared to the cells transfected with inhibitor control (P < 0.05). No significant change in luciferase activity was observed in cells transfected with the mutant IL-18BP 3'UTR construct or pMIR-REPORT plasmid (Fig. 3b), indicating that IL-18BP is the target of miR-134 and could be regulated negatively by miR-134.

Cytokine expression levels in miR-134 mimic- or mimic control-expressing cells. To explore the biologic role of miR-134, we examined the levels of released proinflammatory cytokines in miR-134 over-expressing cells. As shown in Fig. 2a, markedly higher expression of miR-134 in U937 cells occurred after transfection with miR-134 mimic in contrast to low miR-134 expression in control-transfected cells or non-transfection cells (mock), indicating its effective transfection.

To study the link between miR-134 expressions and AOSD pathogenesis, we examined the levels of proinflammatory cytokines, the reported markers of AOSD, in supernatants of miR-134 over-expressing cells. Significantly higher levels of IL-18 were observed in miR-134 over-expressing cells after 24 h of transfection (mean, 39.7 pg/ml) when compared with mimic control-expressing cells (22.7 pg/ml, P < 0.01) (Fig. 2b). However, no significant existed difference in supernatant levels of IL-6, IL-1β, IL-17a, or TNF-α between miR-134 mimic-expressing cells and control-expressing cells or non-transfection cells (Fig. 2c–f).

MiR-134 targets IL-18BP. Bioinformatics analysis using miRNA target predictions (http://www.microrna.org) revealed IL-18BP (GenBank: AF110801.1), an intrinsic inhibitor of IL-18, as a potential seed match for miR-134 in its 3'UTR (Fig. 3a).

To validate whether the IL-18BP is the target of miR-134, luciferase reporter plasmid was constructed by cloning the predicted seed sequence in the human IL-18BP 3'UTR into the pMIR-REPORT luciferase vector; the plasmid with the mutation at the pupative binding site was used as a control. Our results showed that miR-134 mimics significantly decreased (P < 0.01) while miR-134 inhibitors significantly enhanced the luciferase activity in cells transfected with the IL-18BP 3'UTR plasmid compared to the cells transfected with inhibitor control (P < 0.05). No significant change in luciferase activity was observed in cells transfected with the mutant IL-18BP 3'UTR construct or pMIR-REPORT plasmid (Fig. 3b), indicating that IL-18BP is the target of miR-134 and could be regulated negatively by miR-134.

The expression levels of IL-18BP and IL-18 in miR-134 mimic-, miR-134 inhibitor-, or control-expressing cells. Since IL-18BP is a molecular target of miR-134 and the activated macrophage is the major producer of IL-18,20,29, we verified the biologic function of miR-134 in THP-1 cells. As shown in Fig. 3c, significantly lower levels of the released IL-18BP were observed in miR-134 over-expressing cells (mean, 38.6 pg/ml) when compared with miR-134 inhibitor-expressing cells (67.2 pg/ml, P < 0.01), mimic control-expressing cells (52.7 pg/ml, P < 0.05), or non-transfection (50.4 pg/ml, P < 0.05).
Conversely, significantly higher levels of the released IL-18 were observed in miR-134 over-expressing cells (mean, 121.3 pg/ml) when compared with inhibitor-expressing cells (57.3 pg/ml, $P < 0.01$), mimic control-expressing cells (72.0 pg/ml, $P < 0.01$), or non-transfection (62.5 pg/ml, $P < 0.01$) (Fig. 3d).

TLR3 ligand stimulation induced miR-134 up-regulation, caused reduced IL-18BP levels, and elevated free IL-18 levels in AOSD patients. Due to the significantly increased miR-134 levels in PBMCs from AOSD patients after TLR3 ligand poly (I:C) treatment (Fig. 1e), we further examined the levels of

Figure 2. A close link of microRNA-134 (miR-134) expression with levels of IL-18. (a) Comparison of miR-134 expression levels in miR-134 mimic-transfected cells, in control-transfected cells, or in non-transfection cells (mock). Comparison of supernatant levels of proinflammatory cytokines including (b) IL-18, (c) IL-6, (d) IL-1β, (e) IL-17A, and (f) TNF-α released in miR-134 mimic-expressing cells, in mimic control-expressing, and in non-transfection cells (mock) after 24 hours of transfection. Data are presented as mean ± SEM. *$P < 0.05$, versus mimic control-expressing or in non-transfection cells, determined by the ANOVA test with Scheffe correction.
IL-18BP in PBMCs following poly (I:C) treatment. As shown in Fig. 4a, IL-18BP mRNA (right panel) in PBMCs significantly decreased following miR-134 up-regulation (left panel), which is associated with TLR3 ligand stimulation. Additionally, we observed a negative correlation between miR-134 expression and IL-18BP mRNA levels ($r = -0.854$, $P < 0.05$, Fig. 4b) and a positive correlation between miR-134 expression and IL-18 plasma levels in AOSD patients ($r = 0.785$, $P < 0.001$, Fig. 4c).

To verify the results from in vitro cell-based assays, we examined the plasma levels of miR-134, IL-18, and IL-18BP in active AOSD patients, inactive AOSD patients, and controls. As shown in Fig. 4d, significantly higher levels of miR-134 and IL-18 were observed in the plasma of active AOSD patients (mean, 6.4-fold, and 3844.0 pg/ml, respectively) compared to inactive AOSD patients (mean, 2.4-fold, $P < 0.01$ and 1863.6 pg/ml, $P < 0.05$, respectively) and controls (mean, 0.3-fold, $P < 0.001$ and 112.0 pg/ml, $P < 0.001$, respectively). Although the finding has no statistical significance, lower plasma levels of IL-18BP were observed in active AOSD patients (mean, 4441.6 pg/ml) compared to inactive AOSD patients (5572.5 pg/ml, $P = 0.155$).
Figure 4. Toll-like receptor 3 (TLR3) ligand-induced miR-134 contributes elevated free interleukin-18 (IL-18) levels by targeting interleukin-18 binding protein (IL-18BP). (a) TLR3 ligand poly (I:C) stimulation induced miR-134 up-regulation (left panel), caused significantly reduced IL-18BP mRNA levels (right panel) in PBMCs from AOSD patients or healthy controls (HC). Data are presented as mean ± SEM. *P < 0.05, ***P < 0.005. Correlation between miR-134 expressions and IL-18BP mRNA levels (b) or IL-18 levels (c) in AOSD patients is determined by Spearman’s correlation test. (d) Comparison of expression levels of miR-134, IL-18, and IL-18BP in active AOSD patients, inactive AOSD patients, and HC. Data are presented as mean ± SEM. (e) Proposed model for the biologic role of miR-134 in increased level of free IL-18 by targeting IL-18BP in an inflammatory response of AOSD based on the results of this study and previous reports. MyD88, myeloid differentiation primary-response protein 88; NF-κB, nuclear factor κB.
Discussion

In the present study, we investigated differentially expressed miRNAs in plasma from AOSD patients using a miRNA microarray approach and subsequent qRT-PCR validation. Of the differentially expressed miRNAs, we found a significant association of miR-134 expression levels with disease activity and outcome in AOSD patients. Moreover, a significant decrease in miR-134 levels paralleled disease remission of AOSD, indicating that miR-134 expression may be involved in its pathogenesis and serve as an activity indicator as well as a prognostic biomarker of AOSD. Given that IL-18BP acts as the target of miR-134, identified using 3′UTR reporter assay, we demonstrated significantly lower IL-18BP levels and higher IL-18 levels in miR-134 over-expressing cells and in active AOSD patients who had higher miR-134 expressions compared to inactive AOSD patients. The stimulation from TLR3 ligand contributed to miR-134 up-regulation caused declined IL-18BP expression. Based on these observations, we speculate that miR-134 may enhance free IL-18 levels through targeting IL-18BP, and it may act as a potential biomarker of AOSD disease activity. Confirmation is required from further larger studies.

Toll-like receptors have important roles in recognizing pathogens and in initiating inflammatory responses that subsequently prime specific adaptive immune responses during infection. Additionally, accumulating evidence indicates that TLR activation has an essential role in the pathogenesis of several rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus and AOSD. Several studies have reported that TLR activation can modulate miRNA expression in innate immune cells. Our results in the present study show elevated levels of miR-134 following TLR3 activation. TLR3 is primarily responsible for sensing dsRNA, which play a crucial role among viral pathogen-associated molecular patterns. In addition to miR-134, miR-146a and miR-155 have been reportedly induced by TLR3 ligand and regulated proinflammatory cytokine secretion, which were associated with viral infection. In previous studies, the serologic data had suggested that viral infections have a triggering effect in AOSD. Based on our results, we hypothesize that TLR3 might be activated by a viral infection, which then induces miR-134 up-regulation and causes increased circulation of IL-18 in AOSD. Further studies are required to confirm this hypothesis. In addition, our previous study demonstrated that elevated levels of TLR7 signaling molecules and their positive correlation with disease activity in AOSD patients suggest involvement of the TLR7 signaling pathway in the pathogenesis of this disease. No significant association exists, however, between miR-134 levels and TLR7 in the present study, suggesting that miR-134 is specifically up-regulated by TLR3 activation.

MiRNAs have been implicated in important cellular processes, and some research has predicted that one-third of all mRNAs may be regulated by miRNAs. To explore the biologic role of miR-134 and its association with AOSD pathogenesis, we examined the levels of proinflammatory cytokines, the reported markers of AOSD, in supernatants of miR-134 over-expressing cells. The significantly higher IL-18 levels in miR-134 over-expressing cells when compared with control cells, without significant difference in the levels of the other cytokines (IL-1α, IL-6, IL-17A, or TNF-α), suggests a close link of miR-134 expression with levels of IL-18, a key cytokine in AOSD pathogenesis.

IL-18BP, a protein that efficiently regulates the inflammatory activity of IL-18 as a soluble decoy receptor, has been shown to inhibit IL-18–mediated induction of the nuclear factor κB (NF-κB) activation and proinflammatory cytokine production by preventing IL-18 binding to its receptor. The low rate of expression of IL-18BP in miR-134 over-expressing cells in our study may lead to an insufficient binding of IL-18. In support of this hypothesis, we demonstrated significantly higher supernatant levels of IL-18 in miR-134 over-expressing cells when compared with control-expressing cells. Moreover, reduced plasma levels of IL-18BP and increased IL-18 levels were observed in our active AOSD patients who had high levels of miR-134 expression, which represents the possibility of an insufficient binding of IL-18 in AOSD. Previous studies similarly found that serum IL-18BP levels were lower and IL-18 levels higher in active AOSD patients than in those with inactive AOSD. Additionally, we revealed a negative correlation between miR-134 expression and IL-18BP mRNA expression (Fig. 4b) and a positive correlation between miR-134 expression and IL-18 expression (Fig. 4c). Recently, Girard et al. demonstrated that free IL-18 levels are specifically elevated in AOSD compared with other inflammatory diseases, suggesting that IL-18 represents a potential target for the treatment of AOSD. Based on our observations and other previous findings, we hypothesize that miR-134 induced by TLR3 ligand (dsRNA) stimulation may play a biologic role in the elevation of free IL-18 levels by targeting IL-18BP mRNA and by down-regulating IL-18BP expressions, as shown in the proposed model (Fig. 4e).

Although we arrived at a number of novel findings in this pilot study, it had some limitations. First, the lack of any significant association of miR-134 expression with clinical features may be due to the small sample size associated with this clinically heterogeneous and rare disease: its prevalence has been estimated to be lower than 1 case per 100,000 people. To evaluate the application of miR-134 as a biomarker for AOSD, we compared the expression of miR-134 in patients with SLE, which shared partial clinical manifestations with AOSD, as the disease control. Our results showed that increased miR-134 levels were only detected in AOSD patients but not in SLE patients or healthy controls. Moreover, the upregulation of circulating miR-134 levels was positively correlated with AOSD disease activity, suggesting that miR-134 might be an activity indicator of AOSD. In addition, a higher miR-134 expression was observed in our AOSD patients with systemic inflammatory pattern than in those with chronic articular pattern (96.04 ± 35.74 fold vs. 3.04 ± 0.36 fold), but there was no statistical significance (P = 0.143). We thought the decrease of statistical power might be associated with small case numbers of chronic articular AOSD in this study and the confirmation is required from further larger studies. However, our results were consistent with the findings of previous report indicating higher levels of serum IL-18 in AOSD patients with systemic inflammatory pattern compared with those with chronic articular pattern. These observations suggest miR-134 could be a potential biomarker of AOSD. Further large-scale studies are necessary to confirm this hypothesis. Additionally, this study was cross-sectional in design, and, thus, the possibility that miRNA expression changed with therapeutic strategies cannot be excluded. Future studies focusing on miR-134/target relationships ex vivo and an in-depth analysis of the pathogenic mechanisms in AOSD are clearly necessary.
To our knowledge, this is the first study to investigate the role of miRNAs in AOSD pathogenesis. We identified 28 differentially expressed miRNAs in plasma from AOSD patients compared to controls. The upregulation of circulating miR-134 was positively correlated with disease activity, indicating its involvement in AOSD pathogenesis, and it may become a novel diagnostic biomarker. Given that IL-18BP is a target of miR-134; our results from the cell-based functional assay suggest that miR-134 may contribute to AOSD pathogenesis through the downregulation of IL-18BP expression and the subsequent elevation of free IL-18 levels. Additionally, TLR3 activation could induce miR-134 upregulation, which is involved in AOSD pathogenesis. Therefore, the blockade of TLR3 or miR-134 inhibitor may provide potential targets for future therapy in AOSD. Further studies are required to confirm and extend the current findings.

**Methods**

**Subjects.** In the first stage of microarray analysis, 12 consecutive patients with active untreated AOSD who fulfilled the Yamaguchi criteria were enrolled, excluding those with infections, malignancies, or other rheumatic diseases. The disease activity for each AOSD patient was assessed using a modified Pouchot score. Three age-matched healthy adults without any rheumatic disease were included as healthy controls.

For the replication analysis, we enrolled another 18 AOSD patients to conduct real-time QRT-PCR validation of the differentially expressed miRNAs derived from the microarray analysis. Additionally, we enrolled 22 patients who fulfilled the 1997 revised criteria of the American College of Rheumatology (ACR) for SLE, which shared partial clinical manifestations with AOSD, as the disease control. This study was conducted in compliance with the Declaration of Helsinki and has been approved by the Institutional Review Board of TCVGH (CF11224). The methods were carried out in accordance with the approved guidelines and written consent from all participants was obtained.

**Cell Culture.** The peripheral blood mononuclear cells (PBMCs) were immediately isolated from venous blood using Ficoll-Paque PLUS (GE Healthcare Biosciences, Upplands Väsby, Sweden) density gradient centrifugation. The PBMCs and human monocytic cell lines [U937 (ATCC CRL1593; American Type Culture Collection, Rockville, Md.) or THP-1 cells (ATCC TIB-202)] were grown in RPMI medium 1640 (Gibco, Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS), 1x nonessential amino acids, 100 units/ml penicillin, and 100 units/ml streptomycin in an incubator containing 5% CO2 at 37°C. To readily induce differentiation into macrophages, U937 or THP-1 cells (1 × 10⁶ cells/mL) were grown in medium and treated with 10 ng/ml phorbol myristate acetate (PMA) (Sigma, USA) overnight. 293 T cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Thermo Fisher Scientific, USA) supplemented with 10% FBS and incubated at 37°C with 5% CO2.

**TLR ligands stimulation.** To analyze the expression of miR-134 in response to innate immunity ligands, 5 × 10⁶ cells were treated with the following stimuli for 24 h: Pam3CSK4 (TLR1 and TLR2 ligand, 100 ng/ml), peptidoglycan (TLR2 ligand, 10 μg/ml), poly (I:C) (TLR3 ligand, 50 μg/ml), lipopolysaccharides (LPS) from Escherichia coli 055:B5 (TLR4 ligand, 100 ng/ml), flagellin (TLR5 ligand, 100 ng/ml), imiquimod (R837, TLR7 ligand, 1 μg/ml), resiquimod (R848, TLR7 and TLR8 ligand, 1 μg/ml) and CpG (TLR9 ligand, 1 μg/ml). To analyze the effect of TLR3 inhibitor on miR-134 expression, cells were pretreated with 5 nM bafilomycin A1 (Sigma-Aldrich, USA) for 2 h to disrupt TLR3 function before poly (I:C) stimulation. After treatment, the cells were measured using the TaqMan miRNA real-time RT-PCR Assays kit (Applied Biosystems, Thermo Fisher Scientific, USA).

**TLR3 knockdown.** The knockdown reagents were purchased from the National RNAi Core Facility (Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taiwan). The target of lentivirus-based RNA interference (RNAi) for TLR3 was 5'-CCAGTTCAGAAAGAACGGATA-3' (TRCN0000056849). The control RNAi was shLuc. Cells were seeded at an appropriate density on 24-well (0.5 ml per well) tissue culture plates and incubated overnight. Cells were maintained in medium containing 8 mg/ml polybrene. The RNAi lentivirus was added to cells at an MOI of 5 and incubated overnight. Then the medium was replaced with fresh medium containing puromycin for selection and incubated at 37°C with 5% CO2. The knockdown efficiency of the target cells was validated using QRT-PCR (Applied Biosystems, Thermo Fisher Scientific, USA).

**MicroRNA isolation.** Total RNAs were extracted by TRIzol® Reagent (Invitrogen, Thermo Fisher Scientific, USA) and purified by RNeasy MinElute Cleanup kit (QIAGEN, Germany) according to the manufacturer’s instructions. To extract miRNAs from plasma for QRT-PCR validation, synthetic Caenorhabditis elegans miRNA (cel-miR-39, Applied Biosystems, Thermo Fisher Scientific, USA) was added and used as the internal control. Purified RNAs were quantified at OD 260 and 280 nm using a ND-1000 spectrophotometer (Nanodrop Technology, USA), and isolated miRNAs were qualified by capillary gel electrophoresis using a Bioanalyzer 2100 (Agilent Technology, Palo Alto, CA, USA).

**MicroRNA microarray analysis.** MicroRNA microarray analysis was performed with a total of 887 represented miRNAs (Agilent Technologies, Palo Alto, CA, USA) and a slight modification of the technique, which is described elsewhere. Briefly, one hundred nanograms of total RNAs were dephosphorylated and labeled with pCp-Cy3 using Agilent miRNA Complete Labeling and Hyb Kit (Agilent Technologies, USA). Two-fold hybridization buffers (Agilent Technologies, USA) were added to the labeled mixture to a final volume of 45 μL. Scanned images were analyzed using Feature Extraction software version 10.7.3.1 (Agilent Technologies, USA), and data analysis was performed using GeneSpring 7.3.1 (Agilent Technologies, USA). Signal intensities for each spot were calculated by subtracting local background from total intensities. A median value of the four spots for each miRNA was generated. Normalization was performed using a per-chip 75th percentile method that normalizes each chip on its median, allowing comparison among chips. To highlight miRNAs that characterize each group, a per-gene on median normalization was performed.
Quantitative reverse transcription PCR (QRT-PCR). MicroRNA expression was measured and quantified using TaqMan MicroRNA Assays kit (Applied Biosystems, Thermo Fisher Scientific, USA) according to the manufacturer's protocol. QRT-PCR reactions were performed on the StepOnePlus™ Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, USA) using a standard protocol. Each sample was run in triplicate. The small nuclear RNA (Rnu6, for cells) or synthetic cel-miR-39 (for plasma) was used as an internal control gene. The fold expression of the target gene relative to the averaged internal control gene in each sample was calculated using the comparative threshold cycle (ΔΔCt) method and evaluated by 2−ΔΔCt. ΔΔCt = Patient (Ct miRNA gene) − Control (Ct miRNA gene) − Mean of controls (Ct miRNA gene − Ct Rnu6/cel-miR-39).

For mRNA detection, total RNA was subjected to reverse transcription with oligo (dT)Δ primer to target mRNA by using SuperScript® First-Strand Synthesis System (Invitrogen, Thermo Fisher Scientific, USA) according to the manufacturer's instructions, and then cells were incubated at 37 °C overnight. To verify miR-134 is associated with AOSD pathogenesis, we chose proinflammatory cytokines as disease markers15–23 to detect their expression in miR-134 mimic- or inhibitor-expressing cells. After 24 h, cytokine levels in supernatants were determined using ELISA kits for IL-1β (RayBiotech Inc., Norcross, GA, USA), IL-6 (PeproTech Inc., Rocky Hill, NJ, USA), IL-17A (RayBiotech Inc., Norcross, GA, USA), IL-18 (Medical & Biological Laboratories Co., Ltd., Naka-ku, Nogoya, Japan), and TNF-α (R&D Systems, USA) according to the manufacturer's instructions. The viability of the remaining cells was determined by the MTT Cell Proliferation Assay (Promega, USA).

Transfection with miRNA mimics and proinflammatory cytokines release assay. Having demonstrated a significant association of miR-134 expression with disease activity of AOSD, the miR-134 mimic, inhibitor, and control were obtained from Ambion (Thermo Fisher Scientific, USA). U937 or THP-1 cells were transfected with miR-134 mimic, inhibitor, and control (50 nM) using Neon® Transfection system (Invitrogen, Thermo Fisher Scientific, USA) according to the manufacturer's instructions, and then cells were incubated at 37 °C overnight. To verify miR-134 is associated with AOSD pathogenesis, we chose proinflammatory cytokines as disease markers15–23 to detect their expression in miR-134 mimic- or inhibitor-expressing cells. After 24 h, cytokine levels in supernatants were determined using ELISA kits for IL-1β (RayBiotech Inc., Norcross, GA, USA), IL-6 (PeproTech Inc., Rocky Hill, NJ, USA), IL-17A (RayBiotech Inc., Norcross, GA, USA), IL-18 (Medical & Biological Laboratories Co., Ltd., Naka-ku, Nogoya, Japan), and TNF-α (R&D Systems, USA) according to the manufacturer's instructions. The viability of the remaining cells was determined by the MTT Cell Proliferation Assay (Promega, USA).

3′UTR luciferase reporter assays. The wild-type human IL-18BP 3′UTR luciferase reporter plasmid was constructed by amplifying the human IL-18BP mRNA 3′UTR (AF110801.1) and cloning it into the pMIR-REPORT Luciferase vector (Ambion, Thermo Fisher Scientific, USA). Constructs with the AGTCAC to TGACTC mutation at the putative binding site was also generated and used as the control. 293 T cells were co-transfected with 80 ng luciferase reporter plasmid, 40 ng thymidine kinase promoter- Renilla luciferase reporter plasmid, and the indicated miR-134 mimic/mimic control (30 nM) or miR-134 inhibitor/inhibitor control (50 nM). After 36 h, luciferase activities were measured using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions.

To verify the biologic effect of miR-134 on the expression of IL-18BP, we also detected IL-18BP levels in supernatants from miR-134 mimic- or inhibitor-expressing THP-1 cells using an ELISA kit (R&D Systems, USA) according to the manufacturer's instructions.

Statistical analysis. Results are presented as the mean ± standard deviation (SD) or standard error of mean (SEM). The analysis of variance (ANOVA) test or the Student's t-test was used for between-group comparison of the expressions of candidate miRNAs or cytokines. The correlation coefficient was calculated using Spearman's correlation test. Wilcoxon signed rank test was employed to compare the expressions of candidate miRNAs during follow-up in AOSD patients. A probability of less than 0.05 was considered significant.

References
1. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116, 281–297 (2004).
2. Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, function, and decay. Nat Rev Genet. 11, 597–610 (2010).
3. Wei, B. & Wei, G. MicroRNA: critical regulators in TH17 cells and players in diseases. Cell Mol Immunol. 7, 175–181 (2010).
4. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–73 (2013).
5. Sonkoly, E. & Pivarcsi, A. Advances in microRNAs: implications for immunity and inflammatory disease. J Cell Mol. 13, 24–38 (2009).
6. Pauley, K. M., Cha, S. & Chan, E. K. L. MicroRNA in autoimmunity and autoimmune disease. J Autoimmun. 32, 189–194 (2009).
7. Mu, N. et al. A novel NF-kappaB/YY1/microRNA-10a regulatory circuit in fibroblast-like synoviocytes regulates inflammation in rheumatoid arthritis. Sci. Rep. 6, 20059 (2016).
8. Ceribelli, A. et al. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther. 13, N1–10 (2011).
9. Carlsten, A. L. et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 65, 1324–1334 (2013).
10. Zhou, X. et al. Diagnostic value of a microRNA signature in gastric cancer: a microRNA expression analysis. Sci. Rep. 5, 11231 (2015).
11. Wang, H., Peng, W., Ouyang, X., Li, W. & Dai, Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res. 160, 198–206 (2012).
12. Kadavath, S. & Efthimiou, P. Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 45, 1–9 (2013).
13. Rosario, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D'Cruz, D. P. & Shoenfeld, Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catatrophic antiphospholipid syndrome. BMC Med. 11, 185 (2013).
14. Guilpain, P. & Le Quellec, A. The complexity of adult onset Still's disease… and advances still required for its management. BMC Med. 15, 5 (2017).
15. Maria, A. T. J. et al. Adult onset Still's disease (AOSD) in the era of biologic therapies: Dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 13, 1149–1159 (2014).
16. Kawashima, M. et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. *Arthritis Rheum.* **44**, 550–560 (2001).
17. Chen, D. Y., Lan, J. L., Lin, F. J. & Hsieh, T. Y. Proinflammatory Cytokine Profiles in the Sera and in the Pathological Tissues of Patients with Active Untreated Adult Onset Still's Disease. *J Rheumatol.* **31**, 2189–2194 (2004).
18. Choi, J. H. et al. Serum cytokine profiles in patients with adult onset Still's disease. *J Rheumatol.* **30**, 2422–2427 (2003).
19. Chen, D. Y., Lan, J. L., Lin, F. J., Hsieh, T. Y. & Wen, M. C. A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult-onset Still's disease. *Ann Rheum Dis.* **63**, 1300–1306 (2004).
20. Chen, D. Y. et al. Potential Role of Th17 cells in the Pathogenesis of Adult-Onset Still's Disease. *Rheumatology (Oxford).* **49**, 2303–2312 (2010).
21. Priori, R. et al. Interleukin 18: a biomarker for differential diagnosis between adult-onset Still's disease and sepsis. *J Rheumatol.* **41**, 1118–1123 (2014).
22. Chen, D. Y., Hsieh, T. Y., Hsieh, C. W., Lin, F. J. & Lan, J. L. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease. *Arthritis Rheum.* **57**, 1530–1538 (2007).
23. Curtale, G. et al. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. *Blood.* **115**, 265–273 (2010).
24. Xu, G. et al. MicroRNA-149 negatively regulates TLR-triggered inflammatory response in macrophages by targeting MyD88. *J Cell Biochem.* **115**, 919–927 (2014).
25. Wakabayashi, K. et al. Serum 32-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still's disease. *Clin Rheumatol.* **32**, 999–1005 (2013).
26. Kaliakatsos, N. et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3, PKR, and MDA5/RIG-I-mediated differential signaling. *J Immunol.* **181**, 2694–2704 (2008).
27. Betel, D., Wilson, M., Gabow, A., Marks, D. S. & Sander, C. The microRNA.org resource: targets and expression. *Nucleic Acids Res.* **36**, D149–153 (2008).
28. Okamura, H. et al. Cloning of a new cytokine that induces IFN-γ production by T cells. *Nature.* **378**, 88–91 (1995).
29. Ushio, S. et al. Cloning of the cDNA for human IFN-γ factor, expression in Escherichia coli, and studies on the biologic activities of the protein. *J Immunol.* **156**, 4274–4279 (1996).
30. O'Neill, L. A. How Toll-like receptors signal: what we know and what we don't know. *Curr Opin Immunol.* **18**, 3–9 (2006).
31. Joosten, L. A. B., Abdollahi-Roodsaz, S., Dinarello, C. A., O'Neill, L. & Netea, M. G. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. *Nat Rev Rheumatol.* **12**, 344–357 (2016).
32. Chen, D. Y. et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. *Arthritis Res Ther.* **15**, R39 (2013).
33. O'Neill, L. A., Sheedy, F. J. & McCoy, C. E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. *Nat Rev Immunol.* **11**, 163–175 (2011).
34. Miyata, R. et al. Poly(I:C) induced microRNA-146a regulates epithelial barrier and secretion of proinflammatory cytokines in human nasal epithelial cells. *Eur J Pharmacol.* **761**, 375–382 (2015).
35. Yin, Q. et al. MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. *J Virol.* **82**, 5295–5306 (2008).
36. Wouters, J. M., van der Veen, J., van de Putte, L. B. & de Rooij, D. J. Adult onset Still's disease and viral infections. *Ann Rheum Dis.* **47**, 764–767 (1988).
37. Chen, D. Y. et al. Significant association of past parvovirus B19 infection with cytopenia in both adult onset Still's disease and systemic lupus erythematosus patients. *Clin Chim Acta.* **413**, 855–860 (2012).
38. Arlet, J. B., Le, T., Huang, D. B., Pouchot, J. & Piette, J. C. Current concepts on the pathobiology of adult-onset Still's disease. *Rev Med Interne.* **26**, 549–556 (2005).
39. Kim, H. A., An, J. M., Nam, J. Y., Jeon, J. Y. & Suh, C. H. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. *J Rheumatol.* **39**, 1399–1406 (2012).
40. Aizawa, Y. et al. Cloning and expression of interleukin-18 binding protein. *FEBS Lett.* **445**, 338–342 (1999).
41. Novick, D. et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. *Immunity.* **10**, 127–136 (1999).
42. Girard, C. et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. *Rheumatology (Oxford).* **55**, 2237–2247 (2016).
43. Park, J. H. et al. Natural Killer cell cytolytic function in Korean patients with adult-onset Still's disease. *J Rheumatol.* **39**, 2000–2007 (2012).
44. Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1 (IL-1) pathway. *Sci Signal.* **3**, cm1 (2010).
45. Dinarello, C. A., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 binding protein. *Front Immunol.* **4**, 1–10 (2013).
46. Madagur-Joly, G. et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. *Ann Rheum Dis.* **54**, 587–590 (1995).
47. Ichida, H. et al. Clinical manifestations of adult-onset Still's disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18. *Arthritis Care Res.* **66**, 642–646 (2014).
48. Yamaguchi, M. et al. Preliminary criteria for classification of adult onset Still's disease. *J Rheumatol.* **19**, 424–430 (1992).
49. Rau, M. et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. *J Rheumatol.* **37**, 2369–2376 (2010).
50. Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* **40**, 1725 (1997).
51. Taganov, K. D., Boldin, M. P., Chang, K. J. & Baltimore, D. NF-kappaB-dependent induction of microRNA mir-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci USA.* **103**, 12481–12486 (2006).
52. Raymond, C. K., Roberts, B. S., Garrett-Engele, P., Lim, L. P. & Johnson, J. M. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. *RNA.* **11**, 1737–1744 (2005).

**Acknowledgements**

We thank Pei-Ísín Hung, Yi-Ting Lin, Yo-Liang Lai and the Instrument Center of Department of Medical Research of Taichung Veterans General Hospital for technical support. We thank the Biostatistics Task Force of Taichung Veterans General Hospital for statistical analysis support. This work was supported by grants from Taichung Veterans General Hospital (TCVGH-1013804C, TCVGH-1048702D and TCVGH-1067302B).

**Author Contributions**

All authors made substantive intellectual contributions to the present study and approved the final manuscript. T.-L.L. conceived of the study, designed the study, performed data analysis, and drafted and revised the manuscript. Y.-M.C., C.-W.H., and W.-T.H., contributed equally to this work, conceived of the study, performed clinical assessment on study subjects and performed data analysis. H.-C.L., W.-T.H., and K.-T.T. performed data acquisition and data analysis, and Y.-C.Y. conceived of the study, generated the original hypothesis, acquired clinical data, performed data analysis, and drafted and revised the manuscript.
